Screener
Acadia Pharmaceuticals ACAD Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income | 647 | 594 | 1,189 | 1,183 |
| Income before income taxes | 46,473 | 40,211 | 50,454 | 67,990 |
| Income tax expense | 14,973 | 13,545 | 15,317 | 22,337 |
| Net income | $31,500 | $26,666 | $35,137 | $45,653 |
| Earnings per share: | ||||
| Basic | $0.18 | $0.16 | $0.21 | $0.27 |
| Diluted | $0.18 | $0.16 | $0.20 | $0.27 |
| Weighted average common shares outstanding: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's net income?
- Acadia Pharmaceuticals (ACAD) reported net income of $31.5M in Q2 2026.
- How has Acadia Pharmaceuticals's net income changed year-over-year?
- Acadia Pharmaceuticals's net income increased by 18.1% year-over-year, from $26.67M to $31.5M.
- What is the long-term trend for Acadia Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's net income has grown at a 23.5% compound annual growth rate (CAGR), from -$167.87M to $391M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Acadia Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude